RNA (Avidity Corp) Market Value to Book Value Ratio

RNA (Avidity Biosciences Inc) - company brandmark

The current price chart for Avidity Biosciences (RNA) reflects the dynamics of a biopharmaceutical business implementing eco-friendly laboratory waste recycling methods. Avidity Biosciences relies on a robust infrastructure and exclusive patents to maintain high profitability, with the key metric standing at 0.64. Massive R&D investments and stringent FDA oversight create insurmountable barriers to entry for new market participants, cementing the issuer's dominant position.

Avidity Corp (RNA) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026

RNA (Avidity Biosciences Inc): analytical breakdowns and indicator data

- price and consensus price forecast:
Stock Price Avidity Biosciences|RNA - Broker Consensus Forecast
- market capitalization data:
Market Value Avidity|RNA - Business Value
- book capitalization data:
Book Value per Share Avidity Biosciences|RNA - Book Capitalization|Market Capitalization to Book Value Ratio aviditybiosciences.com|RNA - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio Avidity Biosciences|RNA - Long-Term Debt to Equity|Short-Term Debt to Capital Avidity|RNA - Company Total Debt Obligations|Debts to Book Capitalization Avidity
Initial company analysis:RNA, Avidity Biosciences
Manufactured product of Avidity Biosciences Inc

To stress-test assets, it is essential for an investor to compare a company's market value with its net assets to determine the extent of the premium paid for the business. Reliable oligonucleotide logistics and test controls at Avidity Biosciences (RNA) support operational resilience, which, combined with the ratio of market value to book equity, allows for an assessment of capital management efficiency relative to industry peers.

Competitor analysis

Market Capitalization to Book Value Ratio Tempus Labs|QGEN (qiagen.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Ionis (IONS)|Capitalization to Book Value Ratio Repligen Corp|Market Capitalization to Book Value Ratio CRSP|Market Capitalization to Book Value Ratio GeneDx Corp (WGS)|Market Capitalization to Book Value Ratio RARE (Ultragenyx Pharmaceutical)|BEAM - Market Capitalization to Book Value Ratio|SRPT - Market Cap to Net Assets Ratio|TWST - Market Value to Book Value Ratio|10x Genomics Corp - Market Capitalization to Book Value Ratio|Intellia Corp (NTLA) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio Stoke Therapeutics (STOK)|Capitalization to Book Value Ratio biolifesolutions.com|WVE (Wave Life Sciences Ltd.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Maze Therapeutics, Inc. MAZE|Market Cap to Net Assets Ratio Sionna Pharma (SION)|PRME - Market Cap to Book Value Multiple|TSHA (Taysha Gene Therapies) - Market Cap to Net Assets Ratio|uniqure.com (QURE) - Market-to-Book Ratio|Market Cap to Net Assets Ratio MeiraGTx MGTX|REGENXBIO Inc (RGNX) - Market Value to Book Value|Market Capitalization to Book Value Ratio Solid Bio|Market Value to Book Value Ratio Ocugen Pharma|PACB (Pacific Biosciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value BNTC (benitec.com)|DSGN: Market Value to Book Value Ratio|Rocket Pharma - Market-to-Book Ratio|Market Value to Book Value Ratio FDMT (4D Molecular Therapeutics Inc)|LXEO - Market Capitalization to Book Value|KRRO (korrobio.com) - Market Capitalization to Book Value Ratio|editasmedicine.com (EDIT) - Market Cap to Net Assets Ratio|SLN: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value ProQR Therapeutics NV|Codexis, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio SGMO (Sangamo BioSciences)|NAUT - Market Value to Book Value Ratio|Capitalization to Book Value Ratio metagenomi.co MGX|DTIL: Market Capitalization to Book Value Ratio|GBIO - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio BOLD|XCUR (Exicure) - Market-to-Book Ratio|IMNN: Market Value to Book Value Ratio|Market Capitalization to Book Value PHIO|Mustang Bio, Inc. (MBIO) - Market Value to Book Value Ratio|Market Value to Book Value RNAZ (transcodetherapeutics.com)|BNGO - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Applied DNA Corp APDN|bluebird bio, Inc. - Market Capitalization to Book Value Ratio|IPA - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Omega Therapeutics, Inc.|OMIC (Singular Genomics Systems, Inc.) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regulus Therapeutics Inc (RGLS)|Capitalization to Book Value Ratio Syros Pharmaceuticals, Inc|Market Capitalization to Book Value Ratio TBIO|Market Capitalization to Book Value Ratio traconpharma.com (TCON)|Market Capitalization to Book Value Ratio UBX (Unity Biotechnology, Inc.)